Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
Journal of Clinical Pharmacology|January 1, 1988
Pharmacokinetics and pharmacodynamics of oral nizatidineR Vargas, J Ryan, F G McMahon, et al.Journal of Medicine|January 1, 1977
Dose response to fenoprofen in an antipyretic study of fenoprofen and propoxypheneC M Gruber, T CollinsClinical Pharmacology and Therapeutics|April 1, 1990
Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretionD W Schneck, J T Callaghan, R F Bergstrom, et al.Clinical Pharmacology and Therapeutics|February 1, 1985
Intravenous nizatidine kinetics and acid suppressionJ T Callaghan, R F Bergstrom, B D Obermeyer, et al.Alzheimer Disease and Associated Disorders|January 7, 1999
Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB)A E Veroff, N C Bodick, W W Offen, et al.European Journal of Rheumatology and Inflammation|January 1, 1982
A double-blind study comparing benoxaprofen, aspirin, and benoxaprofen plus aspirin in patients with rheumatoid arthritisA S Ridolfo, E M Ashbrook, G E Schmid, et al.Alzheimer Disease and Associated Disorders|January 1, 1997
The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer diseaseN C Bodick, W W Offen, H E Shannon, et al.Cephalalgia : an International Journal of Headache|June 26, 2001
Lanepitant, an NK-1 antagonist, in migraine preventionD J Goldstein, W W Offen, E G Klein, et al.Clinical Pharmacology and Therapeutics|January 11, 1975
Determination of propoxyphene and norpropoxyphene by chemical ionization mass fragmentographyR L Wolen, E A Ziege, C M GruberLancet (London, England)|October 25, 2001
Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trialD J Goldstein, K I Roon, W W Offen, et al.Pageof 4